Applied Therapeutics (APLT) Common Equity (2023 - 2025)
Historic Common Equity for Applied Therapeutics (APLT) over the last 3 years, with Q3 2025 value amounting to -$561000.0.
- Applied Therapeutics' Common Equity fell 10952.14% to -$561000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$561000.0, marking a year-over-year decrease of 10952.14%. This contributed to the annual value of $57.0 million for FY2024, which is 43247.4% up from last year.
- As of Q3 2025, Applied Therapeutics' Common Equity stood at -$561000.0, which was down 10952.14% from $17.4 million recorded in Q2 2025.
- In the past 5 years, Applied Therapeutics' Common Equity registered a high of $72.4 million during Q2 2024, and its lowest value of -$17.1 million during Q4 2023.
- Moreover, its 3-year median value for Common Equity was $5.9 million (2024), whereas its average is $20.0 million.
- As far as peak fluctuations go, Applied Therapeutics' Common Equity soared by 177032.76% in 2024, and later plummeted by 10952.14% in 2025.
- Quarter analysis of 3 years shows Applied Therapeutics' Common Equity stood at -$17.1 million in 2023, then skyrocketed by 432.47% to $57.0 million in 2024, then tumbled by 100.98% to -$561000.0 in 2025.
- Its last three reported values are -$561000.0 in Q3 2025, $17.4 million for Q2 2025, and $36.7 million during Q1 2025.